a molecular prognostic signature built on nine ARGs (e.g., HSP90AA1, NFKB2, PLAU, PTK2, RECQL4, CLU, JAK2, MAP3K5, and S100B) was developed to evaluate the influences of ARGs on the prognosis of BC. Here, CLU is linked to breast cancer.